@article {1384, title = {An Evaluation of the Oral Toxicity of Shwaskas Chintamani Rasa in Wistar Rats for 90-Days Repeated Administration}, journal = {Pharmacognosy Research}, volume = {17}, year = {2025}, month = {April 2025}, pages = {543-551}, type = {Original Article}, chapter = {543}, abstract = {

Objectives: Toxicological research employing Herbo-Metallic (HM) medicine is essential to confirm that such medication has no harmful effects on humans. Despite the fact that the mercury level in Shwaskas Chintamani rasa which is used for respiratory infections has generated safety concerns, there are currently no scientifically validated data on toxicological features and the safety of the drug. As a result, the current study on Shwaskas Chintamani rasa used a sub-chronic study with albino Wistar rats to characterize its toxicological effects. The purpose of this study was to evaluate the toxicity of Shwaskas Chintamani Rasa in Wistar rats following repeated oral administration for 90 days. Materials and Methods: Wistar rats (160-180 g) were divided into four groups (n=6), each containing an equal number of male and female rats. Group II, III and IV were administered with low (51.36 mg/kg, p.o.), moderate (205.44 mg/kg, p.o.), or high (513.6 mg/kg, p.o.) doses of the test drug, respectively, for 13 weeks. The control group received the vehicle (2:3 of honey: water). Physical examination for body weight, food and water intake was carried out. Urine analysis was performed one week before sacrifice. On the 91st day, the animals were sacrificed and hematological, biochemical parameters, organ histology was examined. Results: Study revealed that there were no apparent harmful effects or deaths from Shwaskas Chintamani rasa in 3 dose levels. Conclusion: Thus, this research provides scientific evidence about safety of Shwaskas Chintamani rasa as it does not produce any toxicity in Wistar rats and may be clinically used to treat pregnancy-related illnesses.

}, keywords = {Blood Analysis, Chronic, Gross Pathology, Shwaskas Chintamani, Toxicity}, doi = {10.5530/pres.20251945}, author = {Mahalaxmi Mohan and Shubhangi Hemraj Pawar and Sanskruti Sanjay Kashmire and Shishir Purushottam Pande and Rajshree Abhay Kulkarni and Abhay Narayan Kulkarni} } @article {113, title = {An Open-Label, Multi-Center, Prospective, Interventional, Clinical Study to Evaluate the Efficacy and Safety of Ayuvigo Forte Capsules in Patients Suffering from Oligospermia}, journal = {Pharmacognosy Research}, volume = {11}, year = {2019}, month = {August 2019}, pages = {290-294}, type = {Original Article}, chapter = {290}, abstract = {

Background: Oligospermia refers to semen with a low concentration of sperms. Oligospermia is one of the common causative factors of male infertility. Objectives: The objective of this study was to assess the efficacy and safety of Ayuvigo forte capsule in patients suffering from oligospermia. Materials and Methods: This was an open-label, prospective, interventional, multi-center clinical study. A total of 30 patients were completed the study. All patients were advised to consume two Ayuvigo forte capsules twice daily orally after meals with a cup of milk for 90 days. Data describing quantitative measures are expressed as a mean {\textpm} standard deviation. Results: The mean total sperm count, mean progressive sperm motility, and total number of spermatozoa increased significantly (P \< 0.05) by 90.54\%, 33.65\%, and 98.88\% at the end of the study, respectively. Most patients had shown significant (P \< 0.05) improvement in subjective parameters of low sperm count assessed as per Ayurveda. Furthermore, significant (P \< 0.05) improvement was observed in mean serum free testosterone level. No statistically significant (P \> 0.05) changes were observed in mean serum luteinizing hormone, follicle-stimulating hormone, prolactin, safety laboratory parameters, and vitals. Excellent overall efficacy and tolerability were observed in majority of patients. Conclusion: Ayuvigo forte capsule is safe and effective for the management of oligospermia.

}, keywords = {Ayuvigo forte capsule, Oligospermia, Sperm count, Sperm motility, Testosterone level.}, doi = {10.4103/pr.pr_158_18}, author = {Sanjay M. Tamoli and Narendra B. Mundhe and Devdatta A. Deshmukh and Shishir Purushottam Pande and Rahul Ramkrushna Kamde and Vidyadhar S. Kumbhar and Sachin Anil Upasani and Swapnali B. Mahadik} }